Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor ligand, has shown survival benefits in the treatment of many types of malignant tumors, including non-small-cell lung cancer (NSCLC). We conducted this systematic review and meta-analysis to investigate the ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Xi-Xi, Xu, Ren-Ai, Yu-Ping, Li, Yang, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844428/
https://www.ncbi.nlm.nih.gov/pubmed/27143937
http://dx.doi.org/10.2147/OTT.S96156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844428/
https://www.ncbi.nlm.nih.gov/pubmed/27143937
http://dx.doi.org/10.2147/OTT.S96156

Ejemplares similares